The company said initial efficacy results from a Phase I trial did not provide a competitive benefit-risk profile in CLDN18.2-positive gastric and gastroesophageal cancer.
NEW YORK – Everest Medicines said on Sunday that the US Food and Drug Administration cleared an investigational new drug application (IND) seeking permission to begin studying its mRNA vaccine EVM14 ...
The firm's Heart-2 study of VERVE-102, which is designed to inactivate the PCSK9 gene, is already underway in Canada and the UK.
The PSMA-PET imaging agent will be used for patients who have suspected metastasis and those with suspected cancer recurrence.
Although Eisai decided not to option a HER2-targeted drug under a deal with BlissBio, Angle wants to keep working with the firms to advance its CTC technology.
Alnylam's RNAi TTR Silencing Drug Amvuttra FDA Approved for Transthyretin Amyloidosis Cardiomyopathy
The drug was already sold for TTR amyloidosis with polyneuropathy, and now is available to patients with hereditary or wild-type ATTR-CM.
The firm's LLM-based platform abstracted complex information from medical charts with up to 100 percent accuracy in a pilot study of breast cancer patients.
The firm also said its partner BioNTech won't exercise its option rights for the CD19- and CD22-directed CAR T-cell therapy candidate AUTO1/22.
The firm is also shuttering its allogeneic cell therapy platform and has tasked a new CEO to lead the company through a merger.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback